Using Transcriptional Assessment of Immune Response to Assess Immunosuppression After Liver Transplantation

Launched by UNIVERSITY OF FLORIDA · Sep 26, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring how to better monitor the immune response in patients who have received a liver transplant. The goal is to create a new method that helps doctors decide the right amount of medication to suppress the immune system, which is necessary after a transplant to prevent the body from rejecting the new liver. The study is currently recruiting participants, and it aims to include adults who are at least 18 years old and have had a liver transplant for at least one month.

To be eligible, participants must not have had a previous bone marrow or stem cell transplant, must not be pregnant, and should be able to meet the study's requirements. If you join the study, you'll be closely monitored and may receive personalized medicine based on your body's immune response. This could help improve how well you respond to your transplant and manage your health after surgery. It's important to discuss any questions or concerns with your healthcare provider before considering participation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • At least 18 years of age
• • At least one-month post-transplant
• • Recipient of a liver transplant alone or a simultaneous liver-kidney transplant
• Exclusion Criteria:
• • Unwilling to provide informed consent
• • Recipient of a previous bone marrow or stem cell transplant
• • Pregnant
• • Unlikely to be able to comply with the study requirements, as determined by the PI